Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 2/20 | 0.36 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.36 |
| ▸ | MERTK | Q12866 | 1/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.33 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.33 |
| ▸ | ACP1 | P24666 | 2/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | KHK | P50053 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6833689 | 0.89 | HCRTR1 (0.31) | NPY1RMDM2ADRB2KHK | |
| SCHEMBL6838718 | 0.89 | CCR3 (0.33) | NPY1RMDM2 | |
| SCHEMBL6924606 | 0.88 | HTR4 (0.39) | NPY1RHTR4MERTKACP1TLR7 | |
| SCHEMBL6834013 | 0.88 | NPY1R (0.36) | NPY1RMDM2CYP1A2ADRB2SLC6A4 | |
| SCHEMBL6838673 | 0.88 | NPY1R (0.36) | NPY1RMERTKMDM2ERN1 | |
| SCHEMBL6927043 | 0.88 | NPY1R (0.41) | NPY1RHTR4MERTKACP1 | |
| SCHEMBL6833988 | 0.86 | HTR4 (0.36) | NPY1RHTR4MERTKACP1TLR7 | |
| SCHEMBL6840109 | 0.86 | KDM4E (0.38) | NPY1RHTR4ACP1TLR7CYP1A2 | |
| SCHEMBL6833713 | 0.85 | NPY1R (0.39) | NPY1RHTR4MERTKACP1TLR7 | |
| SCHEMBL6840099 | 0.83 | NPY1R (0.37) | NPY1RHTR4MERTKACP1TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040054182-A1 | 1h-imidazopyridine derivatives | HOKURIKU SEIYAKU CO., LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1256582-A1 | 1H-IMIDAZOPYRIDINE DERIVATIVES | HOKURIKU SEIYAKU CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054182-A1 | 1h-imidazopyridine derivatives | IL2, IL1A, IL4 | NPY1R 1070/4885HTR4 2764/4885MERTK 2059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.